FCP
NVO

Fidelis Capital Partners’s Novo Nordisk NVO Stock Holding History

Fidelis Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,788
Closed -$210K – 514
2025
Q3 		$210K Sell
3,788
-1,006
-21% -$58.9K 0.02% 462
2025
Q2 		$218K Buy
4,794
+611
+15% +$41.6K 0.02% 410
2025
Q1 		$260K Sell
4,183
-10,146
-71% -$838K 0.03% 347
2024
Q4 		$1.18M Sell
14,329
-5,984
-29% -$647K 0.12% 146
2024
Q3 		$2.35M Buy
20,313
+10,500
+107% +$1.4M 0.28% 67
2024
Q2 		$1.17M Buy
9,813
+573
+6% +$75.9K 0.17% 111
2024
Q1 		$1.19M Buy
+9,240
New +$1.1M 0.18% 104

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelis Capital Partners's NVO Position: Q4 2025 in Review

Fidelis Capital Partners sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,788 shares — an estimated $210K sold.

Fidelis Capital Partners first reported a position in NVO in Q1 2024 and held it in 7 quarters. The position peaked at $2.35M in Q3 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Fidelis Capital Partners reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Fidelis Capital Partners sold 3,788 Novo Nordisk shares in Q4 2025, an estimated $210K.
  • Fidelis Capital Partners first reported a position in Novo Nordisk in Q1 2024 and held it in 7 quarters.
  • Fidelis Capital Partners's Novo Nordisk position peaked at $2.35M in Q3 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Fidelis Capital Partners's 13F filing for Q4 2025, filed 9 Feb 2026.